Search Results

Pathophysiology Date & Time Friday, November 3rd / 9:45 AM Abstract Coming Soon Authors and Affiliations Gross About Joshua Gross "I am a neuropharmacologist interested in exploiting GPCR biased signaling to design pharmacotherapies that improve efficacy and minimize side effects for diet-induced metabolic diseases. " Josh Gross on the web Pubmed Google Scholar LinkedIn Twitter Dr.

Josh Pottel About Dr. Josh Pottel "I lead Molecular Forecaster Inc. Josh Pottel on the web Molecular Forecaster LinkedIn BlueSky Google Scholar Twitter Dr.

Josh C Snyder (2012) Dr.

Juan José Fung About Dr. Juan José Fung Dr. Juan José Fung is a Principal Scientist at GPCR Therapeutics, Inc , a drug discovery company focused Juan José Fung on the web LinkedIn GPCR Therapeutics Dr.

Ross Cheloha About this episode Dr. Ross Cheloha is an Investigator at the National Institutes of Health in the Laboratory of Bioorganic Ross and I chatted about his work and transition to an independent investigator; join me to learn more Ross Cheloha on the web NIDDK Cheloha Lab Google Scholar LinkedIn Twitter ResearchGate Dr.

Joshua Gross were enthusiastic about the idea and jumped on board. Dylan Eiger , and Joshua Gross. We are very excited about this event.

Let’s talk about how I support GPCR discovery, pharmacology strategy, and cross-functional execution

aligned with strategy, not spreadsheets Set up clear deliverables across internal and CRO teams Keep cross-functional Let’s talk about how I support GPCR discovery, pharmacology strategy, and cross-functional execution

Analisa Thompson Gray 2, Feyisayo Adegboye 2, Ainsley McDonald-Boyer 3, Fubiao Shi 1, Dianxin Liu 1, Jose

models, along with different cell culture systems, to understand the role of immune cell GPCRs and their cross-talk

unexpected glucagon-derived peptide behavior How future metabolic therapies may evolve based on receptor cross-talk

Let’s talk about how I support GPCR discovery, pharmacology strategy, and cross-functional execution

Let’s talk about how I support GPCR discovery, pharmacology strategy, and cross-functional execution

Core themes: Strategic Planning for Biotech Growth Operational System Design (OS) Cross-functional Team

Her current research focuses on how metabolic GPCRs cross-talk and interact to regulate appetite and

Jose Rizo-Rey as a graduate student to elucidate the mechanisms of neurotransmitter release.

Duvall emphasizes the value of model systems and cross-species discoveries in GPCR biology.

He’s a strong advocate for cross-disciplinary thinking, mentoring young scientists, and building companies

You will walk away with a deeper understanding of GPCR internalization, probe specificity, and the cross-disciplinary

Jose Rizo-Rey as a graduate student to elucidate the mechanisms of neurotransmitter release.

collecting duct, we generated a collecting duct-specific GPR56 knockout (GPR56CD-KO) mouse model by crossing GPR56CD-KO mice were born at predicted Mendelian frequencies, appeared grossly indistinguishable from

Let’s talk about how I support GPCR discovery, pharmacology strategy, and cross-functional execution

be a delicate balancing act, but if the primary purpose is to attack a protected group, the content crosses

be a delicate balancing act, but if the primary purpose is to attack a protected group, the content crosses

; Park, Christopher; Hattori, Takamitsu; Koide, Shohei; Placantonakis, Dimitris New York University Grossman of Medicine" About Dimitris Placantonakis "Dimitris Placantonakis is a neurosurgeon-scientist at NYU Grossman

mouse model (germline Tp53 deletion) with a second floxed allele under the control of Nestin-Cre was crossed